

Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFR α activation loop mutants in advanced gastrointestinal stromal tumor (GIST)

Michael Heinrich¹, Robin Jones², Patrick Schoffski³, Sebastian Bauer⁴, Margaret von Mehren⁵, Ferry Eskens⁶, Philippe Cassier⁷, Olivier Mir⁸, Hongliang Shi⁹, Terri Alvarez-Diez⁹, Mary Ellen Healy⁹, Beni Wolf⁹, Suzanne George¹⁰

¹Oregon Health & Sciences University, Oregon, USA; ²Royal Marsden Hospital/Institute of Cancer Research, London, UK; ³Leuven Cancer Institute, Leuven, Belgium; ⁴University of Essen, Essen, Germany; ⁵Fox Chase Cancer Center, Pennsylvania, USA; ⁶Erasmus MC Cancer Institute, Rotterdam, Netherlands; ⁷Centre Leon Berard, Lyon, France; ⁸Institut Gustave Roussy, Paris, France; ⁹Blueprint Medicines Corporation, Massachusetts, USA; ¹⁰Dana-Farber Cancer Institute, Massachusetts, USA


*EORTC-NCI-AACR Molecular Targets and Cancer
Therapeutics Symposium,
Munich, Germany,
01 Dec 2016*

Disclosures

- BLU-285 is an investigational agent currently in development by Blueprint Medicines Corporation (Blueprint Medicines)
- Dr. Michael Heinrich is an investigator for Blueprint Medicines' ongoing Phase 1 study in unresectable gastrointestinal stromal tumor
- Dr. Michael Heinrich has the following disclosures:
 - Consultant: Blueprint Medicines, Novartis, MolecularMD
 - Equity interest: MolecularMD
 - Research funding: Blueprint Medicines, Deciphera, Ariad
 - Expert testimony: Novartis
 - Patents: four patents on diagnosis and treatment of PDGFR α -mutant GIST

Gastrointestinal Stromal Tumor (GIST)

Most common GI sarcoma




- Cancer of the interstitial cells of Cajal
- Primary tumor usually presents as a stomach or intestinal mass
- Metastatic recurrences spread to liver, peritoneum, and other distant sites
- Chemotherapy has no impact

Activating RTK mutations drive metastatic GIST


KIT ~ 80%

PDGFR α ~ 8%



- Primary mutational hotspots ★
 - KIT Exons 9 or 11
 - PDGFR α D842V Exons 12 and 18
- Resistance mutations ★
 - KIT Exons 13 and 17
 - PDGFR α D842V Exon 18

Advanced GIST has high medical need




Resistance mutation	Prevalence	
	Primary	Secondary
KIT Exon 17	~ 1%	2L ~ 20% 3L ~ 90%
PDGFR α D842V	~ 5-6%	rare

- Activation loop mutations are associated with resistance to therapy
- Approved agents are ineffective against PDGFR α D842V
 - ORR ~ 0%
 - mPFS ~ 3 months


BLU-285 is a highly potent and selective inhibitor of KIT and PDGFR α activation loop mutants

Biochemical profiles

Compound	Activation loop		JM domain/ activation loop
	Exon 18	Exon 17	Exon 11/17
	PDGFR α D842V IC ₅₀ nM	KIT D816V IC ₅₀ nM	KIT V560G/D816V IC ₅₀ nM
BLU-285	0.24	0.27	0.10
imatinib	759	8150	6145
sunitinib	120	207	97.2
regorafenib	810	3640	1685




Tumor regression in KIT exon 11/17* mutant GIST PDX



*del556-558/Y823D

BID, twice daily; IC₅₀, half maximal inhibitory concentration; PDX, patient derived xenograft; QD, once daily
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com)

BLU-285 Phase 1 study



- Primary objectives – determine the MTD and RP2D, and assess safety and tolerability
- Secondary objectives – PK, mutational status, anti-tumor activity

Demography and baseline patient characteristics

Parameter	All patients, N = 36
Age (years), median (range)	61 (41 – 77)
	n (%)
GIST subtype	
KIT mutant	18 (50)
PDGFR α mutant	18 (50)
Metastatic Disease	35 (97)
Largest target lesion size (cm)	
≤ 5	8 (22)
$> 5 - \leq 10$	12 (33)
> 10	14 (39)
pending	2 (6)
#Prior TKI, median (range)	3.5 (0 – 12)
≤ 2	12 (33)
> 2	24 (67)


Initial dose escalation results

- Patients with unresectable GIST
 - Prior imatinib and ≥ 1 TKI
 - PDGFR α D842 mutation regardless of prior therapy
- 3 + 3 dose escalation with **additional accrual to dose levels declared safe at a dose escalation meeting**
- 36 patients enrolled over 12 months
- MTD has not been reached

BLU-285 mg/day	Patients treated by dose N = 36
30	3 + 2 enrichment
60	3 + 3 enrichment
90	3 + 3 enrichment
135	3 + 3 enrichment
200	3 + 2 enrichment
300	3 + 1 enrichment
400	4



- 75% (n=27) of patients remain on treatment, range 0.8 – 12.3 months
- All PDGFR α patients remain on treatment
- 9 patients off treatment (all due to progressive disease)

BLU-285 pharmacokinetics support once daily dosing




- Half-life > 24 hour, supporting QD dosing
- Relatively rapid absorption: $T_{max} \sim 2 - 8$ hr
- Accumulation in plasma: 2.5 – 4.7 -fold after 15 days
- Exposure at 300 mg is at low end of predicted therapeutic range based on KIT Exon 17 mutant xenograft studies

Radiographic response per RECIST 1.1 in PDGFR α D842V GIST (dose level 1, 30 mg)



- 65 yo female, Primary Gastric GIST, PDGFR α D842V
 - Previous surgical de-bulking: stomach; peritoneal metastases x 2; colon
 - Prior response to crenolanib followed by progression
 - Progression on prior dasatinib (no response)
 - Ongoing at Cycle 13 with confirmed partial response (-52% per RECIST 1.1)


Strong clinical activity against PDGFR α D842-mutant GIST at all dose levels




- 14 out of 14 D842-mutant patients with tumor reductions
- All PDGFR α patients remain on treatment

Radiographic response per RECIST 1.1 in heavily pretreated KIT Exon 11/17 GIST (dose level 4, 135 mg)

Baseline




After 24 weeks,
partial response (-62%)



- 57 year old male, KIT Exon 11 (delWK557-8)/Exon 17 (D816V) mutations
 - Prior imatinib, sunitinib, nilotinib, sorafenib, imatinib + BKM120
 - Ongoing at Cycle 8 with confirmed partial response per RECIST 1.1

KIT GIST - early dose-response relationship



NB: The values above/below the bars denote the dose level (mg) QD received by each patient

Best radiographic response with BLU-285 per RECIST 1.1

Best response (per investigator)	PDGFR α N=15 n (%)	KIT N=13 n (%)	Total N=28 n (%)
PR	6 (40)	1 (8)	7 (25)
SD	9 (60)	6 (46)	15 (54)
DCR (PR +SD)	15 (100)	7 (54)	22 (79)
PD	0	6 (46)	6 (21)

- Of 7 partial responses, 6 confirmed; 1 pending (still on treatment)

Adverse events associated with BLU-285

- No DLTs or treatment-related Grade 4 – 5 AEs
- No patient discontinued BLU-285 due to treatment-related toxicity
- 11 (31%) patients had Grade 3 or higher AEs; of these, 3 were considered treatment-related:
 - 1 patient with Grade 3 nausea and vomiting
 - 1 patient with Grade 3 anemia and intratumoral hemorrhage
 - 1 patient with Grade 3 hypophosphatemia
- AEs occurring in $\geq 20\%$ of patients
 - Nausea (42%)
 - Vomiting (33%)
 - Peripheral edema (31%)
 - Fatigue (28%)
 - Constipation (22%)

Summary

- BLU-285 has been well tolerated on a QD schedule at doses of 30 – 400 mg
- Half-life > 24 hours, supports QD dosing
- BLU-285 demonstrates strong clinical activity in PDGFR α D842-mutant GIST at all dose levels
- Significant anti-tumor activity in TKI-resistant, KIT-mutant GIST observed at doses \geq 135 mg with tumor reduction in 4 of 6 patients, including 1 PR
- Dose escalation continues with the goal of maximizing clinical activity in KIT-mutant GIST and to define the MTD and RP2D
- Anticipate initiation of expansion cohorts in first half of 2017

Acknowledgments

- We thank the participating patients, their families, all study co-investigators, and research coordinators at the following institutions:
 - Oregon Health & Sciences University
 - Royal Marsden Hospital/Institute for Cancer Research
 - Leuven Cancer Institute
 - University of Essen
 - Fox Chase Cancer Center
 - Erasmus MC Cancer Institute
 - Centre Leon Berard
 - Institut Gustave Roussy
 - Dana-Farber Cancer Institute